HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
LUNG
Pulmonx Corporation
LUNG lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
LUNG Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Unavailable |
LUNG's revenue is currently stable, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
LUNG PE Valuation
LUNG has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
LUNG Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LUNG has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
LUNG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.01 | +$0.40 |
| Q2 2026 | -$1.16 | +$0.27 |
| Q1 2026 | -$1.30 | +$0.14 |
| Q4 2025 | -$1.33 | +$0.11 |
| Q3 2025 | -$1.41 | +$0.06 |
| Q2 2025 | -$1.43 | +$0.07 |
| Q1 2025 | -$1.44 | +$0.10 |
| Q4 2024 | -$1.44 | +$0.16 |
LUNG has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over LUNG on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over LUNG on profitability, with a higher operating margin.
LUNG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $22.8M | +6.2% |
| Q2 2026 | $22.8M | -4.6% |
| Q1 2026 | $20.6M | -8.7% |
| Q4 2025 | $22.6M | -4.9% |
| Q3 2025 | $21.5M | +5.5% |
| Q2 2025 | $23.9M | +15% |
| Q1 2025 | $22.5M | +20% |
| Q4 2024 | $23.8M | +23% |
LUNG's revenue grew through 2024 and has held roughly level since: $23M last quarter, up 6.2% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -33% | +34 points |
| Q2 2026 | -40% | +22 points |
| Q1 2026 | -63% | +1.7 points |
| Q4 2025 | -44% | +13 points |
| Q3 2025 | -67% | +2.4 points |
| Q2 2025 | -62% | +13 points |
| Q1 2025 | -65% | +13 points |
| Q4 2024 | -56% | +16 points |
LUNG's operating margin was −33% last quarter, up 34 points from the same quarter a year ago, near the top of its range since 2019.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over LUNG on cash generation, producing positive trailing cash flow while its opponent burns cash.
LUNG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$3.2M | +$5.1M |
| Q2 2026 | -$5.2M | -$1.3M |
| Q1 2026 | -$10.1M | +$3.4M |
| Q4 2025 | -$7.1M | -$256K |
| Q3 2025 | -$8.3M | -$593K |
| Q2 2025 | -$4M | +$2.3M |
| Q1 2025 | -$13.5M | -$1.3M |
| Q4 2024 | -$6.8M | +$1.8M |
LUNG has burned cash in almost every quarter: −$26M over the past year, against −$33M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over LUNG on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
LUNG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.7% | +708K shares |
| 1 year | +5.5% | +2.2M shares |
| 3 years | +13% | +5.1M shares |
| 5 years | +18% | +6.7M shares |
LUNG has 43M diluted shares, up 5.5% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2022 | $27,000 |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | $26,000 |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
LUNG Net Leverage
LUNG's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
LUNG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.3 | Neutral |
| Stochastic | 76.2 | Neutral |
LUNG's weekly RSI is 64 (neutral) and its Stochastic is 76 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
LUNG PE vs Healthcare Sector
LUNG has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
LUNG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.22 | 35% above |
| 20 week MA | $2.01 | 49% above |
| 50 week MA | $1.79 | 68% above |
| 100 week MA | $2.87 | 4.5% above |
| 200 week MA | $6.30 | 52% below |
LUNG has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
LUNG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $41.9 | $65.2 | +56% |
| 2021 | $65.2 | $33.0 | -49% |
| 2022 | $33.0 | $7.85 | -76% |
| 2023 | $7.85 | $12.8 | +62% |
| 2024 | $12.8 | $6.70 | -47% |
| 2025 | $6.70 | $2.22 | -67% |
| 2026 YTD | $2.22 | $3.00 | +35% |
LUNG has the edge over HIMS on returns for 2026, with the stronger performance.